Economic evaluation of tegaserod vs. placebo in the treatment of patients with irritable bowel syndrome: An analysis of the TENOR study

Value in Health

Volumn 10, Issue 4, 2007, Pages 238-246

  Bracco, Andrea ^a,e   Jönsson, Bengt ^b   Ricci, Jean Francois ^a   Drummond, Michael ^c   Nyhlin, Henry ^d  

^a NOVARTIS PHARMA AG   (Switzerland)

^b STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^c UNIVERSITY OF YORK   (United Kingdom)

^d ERSTA HOSPITAL   (Sweden)

^e AMGEN INC   (United States)

Author keywords

Clinical trial; Constipation; Irritable bowel syndrome; Nordic; Quality of life; Quality adjusted life years; Tegaserod; Therapeutic

Indexed keywords

TEGASEROD;

ADULT; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ECONOMIC EVALUATION; FEMALE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

EID: 34447568279     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00179.x     Document Type: Article

References (59)

1. Camilleri M, Choi MG. Review article: irritable bowel syndrome. Aliment Pharmacol Ther 1997 11 : 3 15.
2. Talley NJ. Pharmacologic therapy for the irritable bowel syndrome. Am J Gastroenterol 2003 98 : 750 8.
3. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002 123 : 2108 31.
4. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment Pharmacol Ther 2003 17 : 643 50.
5. Hahn BA, Yan S, Strassels S. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digestion 1999 60 : 77 81.
6. Drossman DA. The Rome criteria process: diagnosis and legitimization of irritable bowel syndrome. Am J Gastroenterol 1999 94 : 2803 7.
7. Olden KW. Approach to the patient with severe, refractory irritable bowel syndrome. Curr Treat Options Gastroenterol 2003 6 : 311 17.
8. Lea R, Whorwell PJ. Quality of life in irritable bowel syndrome. Pharmacoeconomics 2001 19 : 643 53.
9. Akehurst RL, Brazier JE, Mathers N, et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics 2002 20 : 455 62.
10. Leong SA. The economic consequences of irritable bowel syndrome: a US employer perspective. Arch Intern Med 2003 163 : 929 35.
11. Kellow JE. Treatment goals in irritable bowel syndrome. Int J Clin Pract 2001 55 : 546 51.
12. Thompson WG, Hungin AP, Neri M, et al. The management of irritable bowel syndrome: a European, primary and secondary care collaboration. Eur J Gastro Hepatol 2001 13 : 933 9.
13. Le Pen C, Ruszniewski P, Gaudin AF, et al. The burden cost of French patients suffering from irritable bowel syndrome. Scand J Gastroenterol 2004 39 : 336 43.
14. Drossman DA, Li Z, Andruzzi E, et al. US householder survey of functional gastrointestinal disorders. Dig Dis Sci 1993 38 : 1569 80.
15. Talley NJ, Gabriel SE, Harmen WS, et al. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995 109 : 1736 41.
16. Fullerton S. Functional digestive disorders (FDD) in the year 2000 - economic impact. Eur J Surg 1998 582 (Suppl. S62 4.
17. Camilleri M, Williams DE. Economic burden of irritable bowel syndrome reappraised with strategies to control expenditures. Pharmacoeconomics 2000 4 : 331 8.
18. Stewart WF, Liberman JN, Sandler RS, et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am J Gastroenterol 1999 94 : 3530 40.
19. Creed F, Ratcliffe J, Fernandez L, et al. Health related quality of life and health care costs in severe refractory irritable bowel syndrome. Ann Intern Med 2001 134 : 860 8.
20. Muller-Lissner SA, Pirk O. Irritable bowel syndrome in Germany. A cost of illness study. Eur J Gastroenterol Hepatol 2002 14 : 1325 9.
21. Martin R, Baron JJ, Zacker C. Irritable bowel syndrome towards a cost-effectiveness management approach. Am J Man Care 2001 7 (Suppl. S268 75.
22. American Lung Association Epidemiology and Statistics Unit. Trends in Asthma Morbidity and Mortality 2003. Available at: http://www.lungusa.org/data/ asthma/astaml.pdf [Accessed March 30 2004 XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999 159 : 813 18.
23. Talley NJ. Evaluation of drug treatment in irritable bowel syndrome. Br J Clin Pharmacol 2003 56 : 362 9.
24. Fennerty MB. Traditional therapies for irritable bowel syndrome: an evidence-based appraisal. Rev Gastroenterol Disord 2003 3 (Suppl. 2 S18 24.
25. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome. A systematic review of randomized, controlled trials. Ann Intern Med 2000 133 : 136 47.
26. Gershon D. Serotonin and its implication for the management of irritable bowel syndrome. Rev Gastroenterol Disord 2003 3 (Suppl. 2 S25 34.
27. Mathis C, Schikowsky A, Thewissen M, et al. Modulation of rectal spinal afferent sensitivity via 5-HT4 receptors. Neurogastroenterol Motil 1998 10 : 459.
28. Prather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000 118 : 463 8.
29. Müller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001 15 : 1655 66.
30. Lefkowitz M, Shi Y, Schmitt C, et al. The 5-HT4 partial agonist, tegaserod, improves abdominal discomfort/pain and normalizes altered bowel function in irritable bowel syndrome (IBS). Am J Gastroenterol 1999 94 : 266.
31. Novick J, Miner P, Krause R, et al. A randomized, double blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002 16 : 1877 88.
32. Tack J, Müller-Lissner S, Bytzer P, et al. Tegaserod provides rapid and sustained relief of overall IBS symptoms and abdominal discomfort/pain when used as repeated treatment in women with IBS-C. Gut 2004 53 : A69.
33. Nyhlin H, Bang C, Elsborg L, et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 2004 39 : 119 26.
34. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome (Cochrane Review). The Cochrane Library. Vol. Issue Chichester : John Wiley & Sons, Ltd., 2004.
35. Ladabaum U. Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications. Aliment Pharmacol Ther 2003 17 : 1021 30.
36. Brooks R with the EuroQol Group. EuroQol: the current state of play. Health Policy 1996 37 : 53 72.
37. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001 33 : 337 43.
38. National Institute for Clinical Excellence (NICE). Guidance for Manufacturers and Sponsors. Available from: http://www.nice.org.uk [Accessed July 2001].
39. Doland P. Modeling valuations for Euroqol health state. Med Care 1997 5 : 1095 108.
40. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQoL: results from UK general population survey. CHE Discussion Paper 138. York : Centre for Health Economics, University of York, 1997.
41. Bushnell DM, Martin ML, Ricci J-F. Performance of the EQ-5D in patients with irritable bowel syndrome. Value Health 2003 6 : 626 7.
42. Vickers AJ, Altman DG. Analyzing controlled trials with baseline and follow up measurements. BMJ 2001 323 : 1123 4.
43. Vickers AJ. The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study. BMC Med Res Methodol 2001 1 : 16.
44. Senn SJ. Covariate imbalance and random allocation in clinical trials. Stat Med 1989 8 : 467 75.
45. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting. current practice and problems. Stat Med 2002 21 : 2917 30.
46. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005 14 : 487 96.
47. van Hout BA, Al MJ, Gordon GS, Rutten FF. Cost, effects and C/E-ratios alongside a clinical trial. Health Econ 1994 3 : 309 19.
48. Löthgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 2000 9 : 623 30.
49. Stinnet A, Mullay J. A new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998 18 : 68 80.
50. Hunink MG, Bult JR, de Vries J, Weinstein MC. Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a parametric bootstrap method. Med Decis Making 1998 18 : 337 46.
51. Efron B, Tibshirani R. Introduction to Bootstrap. New York : Chapman & Hall, 1993.
52. Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004 7 : 518 28.
53. Jönsson B, Cook JR, Pedersen TR. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia 1999 42 : 1293 301.
54. Obenchain RL, Melfi CA, Croghan TW, Buesching DP. Bootstrap analyses of cost effectiveness in antidepressant pharmacotherapy. Pharmacoeconomics 1997 11 : 464 72.
55. Revicki DA, Kaplan RM. Relationship between psychometric and utility-based approaches to measurement of health-related quality of life. Qual Life Res 1993 2 : 477 87.
56. Tougas G, Snape WJ Jr, Otten MH, et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2002 16 : 1701 8.
57. Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double-blind, placebo-controlled, randomised study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003 52 : 671 6.
58. Reilly MC, Barghout V, McBurney CR, Niecko T. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2005 22 : 373 80.
59. Stephenson JJ, Barghout V, Khaler K, et al. Effectiveness of tegaserod therapy on GI-related resource utilization in a managed care population. Am J Managed Care 2005 11 : S35 42.